eagleip, Author at China Patent Strategy

Biotech, China, Court Cases, Courts, Patent Law, prosecution, Supreme People's Court, Top 50 Representative Cases

SPC Upholds $2M RMB Award in China’s First Patent Case on a Biological Deposit

July 4, 2022

On 28 Feb 2022, China’s Supreme People’s Court (SPC) issued its annual “Judgment Digests”, which includes a list of “48 typical cases” highlighting representative SPC decisions in 2021. The Judgment Digests help us understand more about the SPC’s judicial ideology, trial concepts, and adjudication methods in dealing with difficult and sophisticated legal issues as well as new types of IP cases in high tech fields. This case was one of the 48 “typical” cases and deals with how to determine infringement for claims covering biological deposits [1]. Case Background summary FengKe (上海丰科生物科技股份有限公司) is a Shanghai company owning a patent (201310030601.2) claiming a particular white mushroom fungal strain. The patent only…

Read More

eagleip No Comments

Related Posts

Is it Sufficient to Claim an Antibody only by Describing its Antigen?
November 12, 2018

No % homology? How to craft allowable claim scope around sequences to comply with China’s strict written description requirements
November 23, 2018

Diagnostic Claims in China
January 9, 2020
Biotech, China, Court Cases, Patent Law, Patent Linkage, Pharma, Regulatory

China Hands Down First Batch of Patent Linkage “Paragraph IV” Litigation Results

June 30, 2022

China has been implementing a plethora of new laws and measures that are particularly favorable to drug companies, such as patent term extension and patent linkage. Details of the new implementation measures for patent linkage (technically “early dispute resolution mechanisms for drug patents”) came into effect on July 4, 2021. At around the same time, China’s public registration system for innovator companies to list patent associated with marketed drugs (China’s version of the US FDA’s “Orange Book”) began accepting registrations. It has been close to one year since these mechanisms were put in place. Now, the first legal decisions from these patent challenges are coming out. China’s Patent Linkage System…

Read More

eagleip No Comments

Related Posts

Is it Sufficient to Claim an Antibody only by Describing its Antigen?
November 12, 2018

No % homology? How to craft allowable claim scope around sequences to comply with China’s strict written description requirements
November 23, 2018

Diagnostic Claims in China
January 9, 2020
Biotech, China, Court Cases, Courts, Patent Law, Pharma

What Kind of Damage Awards Can You Get in China?

June 16, 2022

Is it worth filing for a patent in China? What kind of damage awards can you get? Pharma companies care more about injunction than damage awards, since it’s quite unlikely that any damage award can compensate for the large amounts of money that may be lost for patent infringement. Chinese courts often issue injunctions in pharma patent litigations (both by the court and administrative enforcement bureaus), though damage awards are possible too. Although not all court cases are publicly available, there have been some recent published cases with pretty high damage awards, ranging from $750K USD to $25M USD. Keep in mind these are cases litigated under the old patent…

Read More

eagleip No Comments

Related Posts

Is it Sufficient to Claim an Antibody only by Describing its Antigen?
November 12, 2018

No % homology? How to craft allowable claim scope around sequences to comply with China’s strict written description requirements
November 23, 2018

Diagnostic Claims in China
January 9, 2020